Callisto currently has 2 trials ongoing for L-Annamycin:
1. Callisto protocol CP-103. Phase I/II Study of Liposomal Annamycin in Patients with Refractory or Relapsed Acute Lymphocytic Leukemia. This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum tolerated dose (MTD) of Liposomal Annamycin and to evaluate the safety of Liposomal Annamycin in patients with refractory or relapsed acute lymphocytic leukemia.
For further information, please go to www.clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT00271063
How to enroll: Please go to www.clinicaltrials.gov and search for NCT00271063 to look up enrolling site locations.
2. Callisto protocol CP-105. Phase I Study of Liposomal Annamycin in Children and Young Adults with Refractory or Relapsed Acute Lymphocytic Leukemia or Acute Myelogenous Leukemia. This is a Phase I, multi-center, open-label, dose escalation, MTD study of liposomal annamycin in children and young adults with refractory or relapsed ALL or AML.
For further information, please go to www.clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT00430443
How to enroll: Please go to www.clinicaltrials.gov and search for NCT00430443 to look up enrolling site locations.